Interventions for reducing inflammation in familial Mediterranean fever

Wu, Bin; Xu, Ting; Liu, You‐Ping; Yin, Xi

doi:10.1002/14651858.cd010893.pub3

Cited by 12 publications

(10 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Cochrane review evaluating drugs used for colchicineresistant FMF (anakinra, rilonacept, etanercept, infliximab, thalidomide, IFN-alpha, herbal dietary supplements, and non-steroidal anti-inflammatory drugs) concluded that there were still limited randomized controlled studies for the treatment of FMF. 9 Few studies consisting of limited cases showed benefits with IFN-alpha. IFN prevented most of the FMF attacks or attenuated the attack intensity.…”

Section: Discussionmentioning

confidence: 99%

Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report

Öztürk

2019

Arch Rheumatol

View full text Add to dashboard Cite

Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder. It is characterized by recurrent attacks of fever, peritonitis, pleuritis, and synovitis and common in Mediterranean people including Turks, Arabs, Armenians, and non-Ashkenazi Jews. 1 The responsible gene for FMF is MEFV located on chromosome 16p. Multiple sclerosis (MS) is the most common demyelinating disease of central nervous system. MS is characterized by inflammation and demyelination and caused by several environmental and genetic factors. Patients with FMF have a susceptibility to develop MS. Mutations of genes like MEFV encoding pyrin protein may promote development of MS disease. 2 Akman-Demir et al. 3 suggested a four-fold increased rate of FMF among MS patients. Currently, there is no curative treatment for both diseases. Immunomodulatory drugs display beneficial effects by decreasing severity and frequency of MS attacks. CASE REPORT A 37-year-old male patient was admitted to our department with numbness of lower extremities and difficulty in walking in September 2017. He had been suffering from numbness for more than three months and from gait disturbance for the last month. A few years before, he had numbness on lower extremities but he did not admit to any hospital and his complaints were completely resolved within two weeks. In his neurological examination, hypoesthesia in right ABSTRACT Multiple sclerosis (MS) is the most common demyelinating disease in Turkey while familial Mediterranean fever (FMF) is the most common periodic fever syndrome worldwide. In this article, we report a 37-year-old male patient admitted with complaint of difficulty in walking. He had been taking colchicine at admission for 27 years. Despite this therapy, he had been experiencing twice monthly severe FMF attacks. After systemic and neurological examinations, laboratory tests and cranial and spinal magnetic resonance imaging, he was diagnosed as MS. Interferon (IFN) beta-1a was initiated three times/weekly subcutaneously for MS treatment. He stopped colchicine treatment after five months of IFN treatment because he did not suffer from any FMF attacks. He is still attack free for both diseases for a follow-up duration of 12 months. IFN beta is one of the most preferred agents for MS treatment but not one of the agents used for the treatment of FMF. Interferon beta can be a treatment of choice in patients with coincident FMF and MS and can be used in colchicine-resistant patients after being studied in systematic clinical studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report

Öztürk

2019

Arch Rheumatol

View full text Add to dashboard Cite

show abstract

“…Захворювання має переваж не поширення у середземноморській популяції з характерними клінічними ознаками. Колхіцин розглядають як препарат пер шої лінії для стандартного лікування сімейної середземномор ської лихоманки [6][7][8]. У 87% випадків його застосування значно зменшує тяжкість перебігу, тривалість загострення та частоту нападів [30,31].…”

Section: сімейна середземноморська лихоманкаunclassified

“…

…”

unclassified

Колхіцин: Нові Можливості Клінічного Застосування Давно Відомого Препарату

Осадчий¹,

часопис»²

2021

UMJ

View full text Add to dashboard Cite

Редакція журналу «Український медичний часопис» Анотація. Колхіцин як потужний протизапальний препарат давно і активно застосовують у ревматології, переважно для лі кування пацієнтів із подагрою, а також при системних васкулітах, хворобі Бехчета та сімейній середземноморській лихо манці [1][2][3][4][5][6][7][8]. Однак потенціал протизапальних можливостей колхіцину далеко не вичерпаний. Останнім часом з'явилося чи мало досліджень, що підтверджують його високу ефективність у разі одночасного застосування з іншими препаратами для зменшення вираженості фатальних ускладнень в кардіології (порушення серцевого ритму, хронічна коронарна недостатність, легенева гіпертензія, інфаркт міокарда, перикардит) та при онкологічних захворюваннях [9][10][11][12][13][14]. Серед несподіванок, які остан нім часом виявлено у клінічних випробовуваннях колхіцину, -його надзвичайно висока ефективність при лікуванні пацієн тів із COVID19. За попередніми результатами клінічного дослідження COLCORONA, застосування колхіцину значно знизило летальність та частоту госпіталізації амбулаторних пацієнтів із COVID19 [15]. Маючи досить давню історію застосування, як з'ясувалося, колхіцин далеко не вичерпав свої лікувальні можливості й може успішно використовуватись у різних клінічних ситуаціях із високою ефективністю. У цій публікації узагальнено раніше відомі та з'ясовані нові можливості застосування кол хіцину у сучасній медичній практиці. Ключові слова: колхіцин, подагра, системні васкуліти, хвороба Бехчета, сімейна середземноморська лихоманка, перикардит, COVID19.Рисунок 1 Механізм дії колхіцину [19] ROS (Reactive Oxygen Species) -активні форми кисню.

show abstract

“…2015, Wu et al . 2018), and could theoretically reduce the consequences of SPAID by blocking amyloid deposition and serum amyloid A synthesis, downregulation of inflammatory pathways, and modulation of innate immunity (Livneh et al . 1994, Leung et al .…”

Section: Introductionmentioning

confidence: 99%

A survey on Shar Pei autoinflammatory disease in the United Kingdom

Work

Scudder

Hjellegjerde

et al. 2023

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To characterise the fever episodes attributed to Shar Pei autoinflammatory disease and to identify common diagnostic and management strategies in the United Kingdom. A secondary objective was to determine risk factors associated with Shar Pei autoinflammatory disease fever episodes. Methods A retrospective survey was performed to characterise episodes of Shar Pei autoinflammatory disease fever and to identify commonly used treatments in affected dogs. Clinical data were collected from owners and veterinarians. Frequencies of previously proposed risk factors (skin thickness and folding, muzzle conformation) and comorbid conditions were compared between dogs that had exhibited fever episodes consistent with Shar Pei autoinflammatory disease and those who had not. Results At least one episode of fever attributed to Shar Pei autoinflammatory disease was reported in 52 of 106 (49%) Shar Pei. Nine other dogs had fever episodes consistent with Shar Pei autoinflammatory disease reported by their owners but not by veterinarians. Median rectal temperature at presentation for Shar Pei autoinflammatory disease fever was 40.1°C [104.2°F] (39.9 to 41.3°C [103.8 to 106.3°F]) and owners reported associated hyporexia (n=33, 63%) and vomiting (n=8, 15%) more frequently than veterinary records (n=22, 42% and n=0, 0%, respectively). The median number of veterinary appointments for Shar Pei autoinflammatory disease was two per dog (1 to 15) while owners reported a median of four episodes per dog per year. None of the assessed phenotypic variants or comorbidities were significantly associated with exhibiting Shar Pei autoinflammatory disease fever episodes. Clinical Significance Episodes of Shar Pei autoinflammatory disease fever were reported approximately twice as frequently by owners compared to veterinary records, suggesting the burden of this condition may be underestimated by veterinarians. Specific risk factors for Shar Pei autoinflammatory disease fever were not identified.

show abstract

Interventions for reducing inflammation in familial Mediterranean fever

Cited by 12 publications

References 80 publications

Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report

Familial Mediterranean Fever and Multiple Sclerosis Successfully Treated With Interferon Beta-1a: A Case Report

Колхіцин: Нові Можливості Клінічного Застосування Давно Відомого Препарату

A survey on Shar Pei autoinflammatory disease in the United Kingdom

Contact Info

Product

Resources

About